A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

Phase 3CompletedNCT01999322

Novo Nordisk A/S37 enrolled

Overview

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external continuous subcutaneous insulin infusion (CSII) system in adult subjects with type 1 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 1

Interventions

Faster-acting insulin aspartDRUG

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

insulin aspartDRUG

Administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, age at least 18 years at the time of signing inform consent * Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months at the time of screening (Visit 1) * Currently treated with insulin aspart, insulin lispro or insulin gluisine for at least 3 months prior to screening (Visit 1) * Using an external CSII system for the previous 6 months prior to screening (Visit 1) * HbA1c (glycosylated haemoglobin) below or equal to 9.0% as assessed by central laboratory * Body Mass Index (BMI) 20.0-35.0 kg/m\^2 Exclusion Criteria: * History of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6 months prior to screening (Visit 1) * History of abscess at the infusion site within 6 months prior to screening (Visit 1) * Hypoglycaemic unawareness as judged by the Investigator or history of severe hypoglycaemic episodes requiring hospitalization within the last 6 months prior to screening (Visit 1)

Locations (2)

Novo Nordisk Investigational Site

Atlanta, Georgia, United States

Novo Nordisk Investigational Site

Neuss, Germany

Outcomes

Primary Outcomes

Number of Microscopically Confirmed Episodes of Infusion Set Occlusions

The number of microscopically confirmed episodes of infusion set occlusions during 6 weeks of treatment. Episodes of infusion set occlusions were confirmed by microscopic examination of the infusion sets at each routine weekly visit and infusion sets that had been changed prematurely because of leakage, unexplained hyperglycaemia or suspicion of occlusion (observation of a plug).

Time frame: During 6 weeks of treatment

Secondary Outcomes

Number of Unexplained Episodes of Hyperglycaemia (Confirmed by Self-measured Plasma Glucose (SMPG))

Unexplained hyperglycaemia was defined as a confirmed plasma glucose value ≥ 16.7 mmol/L (300 mg/dL) and was unexplained (i.e., no apparent medical, dietary, insulin dosage or pump failure reason)

Time frame: During 6 weeks of treatment

Number of Episodes of Possible Infusion Set Occlusions

Episodes of possible infusion set occlusions were defined as infusion sets changed due to suspicion of occlusion, leakage or unexplained hyperglycaemic episode. Possible occlusion excluded technical reasons. This endpoint was calculated from the recorded date/times of changes of infusion set combined with the subjects' own assessment.

Time frame: During 6 weeks of treatment

Number of Premature Infusion Set Changes

A premature infusion set change was defined as not being a routine change. This was defined as an infusion set changed at home due to "suspicion of occlusion", "leakage", "unexplained hyperglycaemic episode", "infusion site reaction", "technical reason", or "other". The change of infusion set at a site visit was considered a routine change unless an occlusion was actually suspected at the site.

Time frame: During 6 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.